Diabetes Drugs and Cardiovascular Safety.
10.3803/EnM.2016.31.2.239
- Author:
Ji Cheol BAE
1
Author Information
1. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea. drkuri10@gmail.com
- Publication Type:Review
- Keywords:
Diabetes mellitus;
Cardiovascular diseases;
Heart failure;
Hypoglycemic agents
- MeSH:
Cardiovascular Diseases;
Diabetes Mellitus;
Heart Failure;
Humans;
Hypoglycemic Agents;
Mortality;
Risk Assessment;
Risk Factors;
United States Food and Drug Administration
- From:Endocrinology and Metabolism
2016;31(2):239-244
- CountryRepublic of Korea
- Language:English
-
Abstract:
Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial effect of improved glycemic control on cardiovascular complications has been well established. However, the rosiglitazone experience aroused awareness of potential cardiovascular risk associated with diabetes drugs and prompted the U.S. Food and Drug Administration to issue new guidelines about cardiovascular risk. Through postmarketing cardiovascular safety trials, some drugs demonstrated cardiovascular benefits, while some antidiabetic drugs raised concern about a possible increased cardiovascular risk associated with drug use. With the development of new classes of drugs, treatment options became wider and the complexity of glycemic management in type 2 diabetes has increased. When choosing the appropriate treatment strategy for patients with type 2 diabetes at high cardiovascular risk, not only the glucose-lowering effects, but also overall benefits and risks for cardiovascular disease should be taken into consideration.
